Monopar Therapeutics shares technical analysis: Upward price move faces $76.38 resistance
Monopar Therapeutics (MNPR) stock is trading at $73.74, up 3.05% today. The price is positioned above its key short-term moving averages and remains beneath medium- and long-term trend indicators.
70.0700
74.8000
Highlights
- MNPR/USD trades above near-term average but remains below key medium- and long-term moving averages, indicating short-term buying but longer-term selling pressure.
- Mixed momentum readings and overbought intraday signals show buyers dominate for now, yet trend confirmation is lacking.
- Price consolidates between $71.10 and $76.38 over the next 2 to 3 days with a 52% probability of a move higher.
Mixed momentum and technical boundaries shape intraday bias
MNPR faces technical cross-currents, with the price closing above the MA-20 at $70.59 but below the MA-50 at $73.99 and the MA-200 at $76.90. Support is identified at the Ichimoku Kijun level of $71.76, while resistance comes in at $76.38. Momentum signals remain conflicted: both RSI (51.42) and CCI give buy signals, and ADX is also positive; meanwhile, MACD delivers a robust sell. Stochastic RSI and Bull/Bear Power are in overbought territory and reinforce the dominance of buyers intraday, though the Awesome Oscillator remains neutral, suggesting mixed conviction among participants.
Slight bullish tilt as price consolidation signals indecision
Looking ahead to the next two to three trading sessions, MNPR is likely to move within a $71.10 to $76.38 volatility band relative to current levels. The likelihood of a further rise is slightly stronger at 52%, so a breakdown beneath $71.10 would mark a bearish scenario and may trigger added downside momentum. As long as consolidation persists within this corridor, price action will reflect an indecisive market, with a break above $76.38 required for sustained upside progress.
Earlier, analysts noted that Monopar Therapeutics stock was under persistent bearish pressure, with downside risk outweighing breakout potential. The latest technical readings introduce a more balanced outlook, with traders advised to monitor the $76.38 level as a potential inflection point for renewed upside momentum.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
